Association of Anorexia Nervosa With Risk of Cancer
A Systematic Review and Meta-analysis

Ferrán Catalá-López, PhD; Jaume Forés-Martos, MSc; Jane A. Driver, MD; Matthew J. Page, PhD; Brian Hutton, PhD; Manuel Ridao, PhD; Adolfo Alonso-Arroyo, PhD; Diego Macías Saint-Gerons, PhD; Ricard Gènova-Maleras, MSc; José M. Valderas, MD, PhD; Eduard Vieta, MD, PhD; Alfonso Valencia, PhD; Rafael Tabarés-Seisdedos, MD, PhD

Abstract

IMPORTANCE Anorexia nervosa is recognized as an important cause of morbidity in young people. However, the risk of cancer in people with anorexia nervosa remains uncertain.

OBJECTIVE To evaluate the association of anorexia nervosa with the risk of developing or dying of cancer.

DATA SOURCES MEDLINE, Scopus, Embase, and Web of Science from database inception to January 9, 2019.

STUDY SELECTION Published observational studies in humans examining the risk of cancer in people with anorexia nervosa compared with the general population or those without anorexia nervosa. Studies needed to report incidence or mortality rate ratios (RRs).

DATA EXTRACTION AND SYNTHESIS Screening, data extraction, and methodological quality assessment were performed by at least 2 researchers independently. A random-effects model was used to synthesize individual studies. Heterogeneity ($I^2$) was assessed and 95% prediction intervals (PIs) were calculated.

MAIN OUTCOMES AND MEASURES All cancer incidence and cancer mortality associated with anorexia nervosa. Secondary outcomes were site-specific cancer incidence and mortality.

RESULTS Seven cohort studies published in 10 articles (42,602 participants with anorexia nervosa) were included. Anorexia nervosa was not associated with risk of developing any cancer (4 studies in women; RR, 0.97; 95% CI, 0.89-1.06; $P = .53$; $I^2$, 0%; 95% PI, 0.80-1.18; moderate confidence). Anorexia nervosa was associated with decreased breast cancer incidence (5 studies in women; RR, 0.60; 95% CI, 0.50-0.80; $P < .001$; $I^2$, 0%; 95% PI, 0.44-0.83; high confidence). Conversely, anorexia nervosa was associated with increased risk of developing lung cancer (3 studies in women; RR, 1.50; 95% CI, 1.06-2.12; $P = .001$; $I^2$, 0%; 95% PI, 0.19-16.46; low confidence) and esophageal cancer (2 studies in women; RR, 6.10; 95% CI, 2.30-16.18; $P < .001$; $I^2$, 0%; low confidence).

CONCLUSIONS AND RELEVANCE Among people with anorexia nervosa, risk of developing cancer did not differ compared with the general population, but a significantly reduced risk of breast cancer was observed. Understanding the mechanisms underlying these associations could have important preventive potential.

Key Points

Question Are people with anorexia nervosa at a higher risk of developing or dying of cancer compared with those without anorexia and the general population?

Findings In this systematic review and meta-analysis of 7 cohort studies including more than 42,000 participants with anorexia nervosa, there was no association of anorexia nervosa with overall cancer incidence or mortality. Anorexia nervosa was inversely associated with breast cancer incidence but positively associated with risk of developing lung and esophageal cancer.

Meaning There was no association of anorexia nervosa with risk of cancer overall and few associations of anorexia nervosa with risk of site-specific cancer.

+ Supplemental content

Author affiliations and article information are listed at the end of this article.


Open Access. This is an open access article distributed under the terms of the CC-BY License.
Introduction

Almost 3.4 million young people throughout the world have anorexia nervosa. Anorexia nervosa is characterized by a severe restriction of caloric intake, extremely low body weight, fear of gaining weight or of becoming fat, and disturbance of body image. Anorexia nervosa is more commonly reported by young women and girls, but the disorder is increasingly being reported by boys, men, and women older than 40 years. Genetic factors and hormonal changes may influence risk, psychosocial and interpersonal factors can trigger onset, and changes in molecular pathways and cellular networks in the brain are associated with the illness and its comorbidities.2-4

Cancer is the second leading cause of death worldwide,5,6 with more than 9.6 million deaths in 2017.6 Multiple studies and meta-analyses suggest that excess body weight is a risk factor of several cancers.7-9 For example, a recent umbrella review8 found evidence of an association of body mass index (BMI) with cancers of digestive organs, hormone-related cancers, uterine cancer, kidney cancer, and multiple myeloma and also of adiposity with the risk of colorectal cancer, gallbladder cancer, gastric cancer, ovarian cancer, and multiple myeloma. The underlying mechanisms of the association of excess body weight with cancer are complex and are not yet fully understood.

Research on how reducing body weight might lower the risk of developing cancer is limited, to our knowledge. Energy restriction (or calorie restriction) has been found to be protective against the development of cancer in experimental animal studies.10 In addition, certain calorie-limited diets or fasting could influence the risk of developing cancer. Anorexia nervosa, an excessive form of calorie restriction associated with pathological weight loss, has been proposed as a biomarker of energy restriction in humans.11-13 Several studies have evaluated whether there is a reduction in cancer development among people with anorexia nervosa.12-14 However, to our knowledge, there are no systematic reviews and meta-analyses investigating the strength of the evidence of the potential associations of anorexia nervosa with cancer. In this study, we aimed to evaluate the association of anorexia nervosa with the risk of developing or dying of cancer.

Methods

We followed the current methods recommendations for systematic reviews15,16 and developed a protocol (PROSPERO registration number: CRD42017067462)17 to comply with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline statement for reporting this study. We also reported this study in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline. Our methods are briefly described here and explained in more detail in the published protocol17 and in eTables 1-7 in the Supplement.

Search Strategy and Selection Criteria

One of us (A.A.-A.) searched MEDLINE, Scopus, Embase, and the Web of Science to identify all relevant observational studies in humans that examined the association of anorexia nervosa with the risk of cancer published from database inception to January 9, 2019, without language restrictions. The main search strategy for MEDLINE is presented in eTable 3 in the Supplement. This search strategy was adapted to fit with other databases. To supplement these searches, references of all relevant primary studies and review articles were also screened to identify additional data sources.

To be included, primary studies had to be observational (ie, cohort or case-control) studies of people with anorexia nervosa (according to standard operationalized diagnostic criteria, ie, International Classification of Diseases, Ninth Revision [ICD-9] codes 307.1 or 307.54 or ICD-10 codes F50.0-F50.1) and report the incidence or mortality rate ratios (RRs) for the risk of cancer in patients with anorexia nervosa compared with the general population or those without anorexia nervosa or have enough data (ie, number of cases and sample size, observed and expected cases) to compute these estimates. We excluded studies in which anorexia nervosa was not the exposure of interest and in which cancer was not reported as the outcome. Studies not presenting study-specific data or
sufficient data for an outcome measure to be calculated were also excluded. We excluded case reports, case series, in vitro studies, and animal studies.

Two of us (F.C.-L. and J.F.-M.) independently screened the titles and abstracts of articles retrieved from the literature search, and the full-texts of potentially eligible articles were obtained and further assessed for final inclusion. Disagreements were resolved through discussions until a consensus was reached.

Outcomes
The primary outcomes were all cancer incidences and cancer mortalities (all malignant neoplasms; ICD-9 codes 140-209; ICD-10 codes C00-C97). Given the varied biology of cancers, the risk of incident site-specific cancers and the risk of fatal site-specific cancers were evaluated as secondary outcomes (eTable 1 in the Supplement).

Data Extraction and Quality Assessment
Two of us (F.C.-L. and J.F.-M.) independently extracted article data, including first author, publication year, period of recruitment, country, study design, setting, coverage, mean or median age (or age range), proportion of female participants, race/ethnicity, parity status, profile of tobacco smoking, ascertainment of cancer diagnosis and diagnostic criteria, consideration of confounding factors, the number of participants with cancer, and maximally adjusted RR estimates with 95% CIs from the included studies. For duplicate study publications, we considered only the report with the most informative and complete data. When relevant outcome data were not available, we directly contacted the corresponding author of the study to request the information. Two pairs of us (J.F.-M., M.J.P., M.R., and/or D.M.S.-G.) independently undertook methodological quality assessment of included studies using the Newcastle-Ottawa scale18 and allocated stars for adherence to the prespecified criteria. This scale ranges from 0 stars (lowest quality) to 9 stars (highest quality) and judges each study regarding selection of study groups, comparability, and ascertainment of the outcome. We considered studies with 0 to 3 stars to represent high risk of bias; 4 to 6 stars, moderate risk of bias; and 7 to 9 stars, low risk of bias. Discrepant scores were resolved by discussion and consensus among us.

Statistical Analysis
To measure the association of anorexia nervosa with cancer, we performed meta-analysis using the inverse–variance weighted random-effects model19 to pool weighted RRs of cancer risk estimates. Random-effects meta-analysis produces a more generalizable result by considering both within-study and between-study variation by incorporating the heterogeneity of effects into overall analyses. We assessed heterogeneity between studies using the P value of Cochran Q test20 and the I² statistic (with 95% CIs).21 The I² statistic ranges from 0% to 100%, with values of 0% to 25% indicating low heterogeneity and 75% to 100% indicating high heterogeneity.15 In comparisons that included 3 or more studies, we also calculated the 95% prediction intervals (PIs), which further account for heterogeneity between studies and indicate the uncertainty for the effect that would be expected in a new study examining that same association.22 To assess the robustness of pooled results and explore possible reasons for heterogeneity, prespecified subgroup analyses were performed according to sex (female or male), and cancer types according to relationship with smoking (smoking-related cancer sites or other cancer sites) or sex hormones (cancers occurring in hormone-sensitive tissues, such as breast, ovary, uterus, prostate, and colorectal, where sex hormones exert an important influence in cancer etiopathogenesis and progression, or other cancer sites).17 For the secondary outcome of breast cancer incidence, we conducted a specific analysis among women and girls based on parity status (parous or nulliparous women) and age at receiving first diagnosis of anorexia nervosa (prior to age 20 years or at 20 years or older).13 We performed a post hoc sensitivity analysis excluding studies that had possible geographical and temporal overlapping study samples (eg, 2 previously published studies in Denmark14 and Sweden23-25).
considering only data from the study with the greatest person-years. P values were determined using the Woolf method. P values were 2-tailed, and statistical significance was set at less than .001. We conducted data analysis using the metan package in Stata statistical software version 15 (StataCorp). With the publication of this article, the full data set will be freely available online in the Open Science Framework (https://osf.io/Y6WQN/). We applied a set of criteria to classify the credibility of the evidence from meta-analysis based on the Global Burden of Disease and World Cancer Research Fund criteria26,27 and GRADE system28 (eTable 7 in the Supplement).

Results

Relevant Literature Identified

We screened 358 titles and abstracts, followed by 59 full-text articles (Figure 1). Seven cohort studies published in 10 articles,12,13,23-25,29-33 including 42 602 participants with anorexia nervosa, met our inclusion criteria.

Description of Studies and Participants

Table 1 summarizes the characteristics of the included studies. All studies were published in English from 2001 through 2018. Five studies were from Europe (Denmark,12,29,32 Finland,29,32 Sweden,13,23-25,29,32 and the United Kingdom11) and 2 studies30,33 were from North America (the United States). Six studies were retrospective cohorts12,13,23-25,29-32 and 1 was a prospective cohort.33 Median (range) follow-up was 13.3 (5.4-27.1) years. The number of participants with anorexia nervosa varied from 275 to 24 332, and the number of cancer cases ranged from 2 to 389. The proportion of female participants varied from 60.5% to 100%.

There were 79 individual study estimates for all types of cancer and 22 site-specific cancer outcomes (eTable 5 in the Supplement). All 7 studies provided adjusted risk estimates (eg, adjusted for age, sex, and calendar year). Breast cancer was the most studied site-specific outcome, accounting for 108 cases (19.8%) in 5 studies. Bladder, bone, prostate, and testicular cancer only accounted 1 case each, representing 0.7% of all cancer cases (Figure 2). Regarding the methodological quality (eTable 6 in the Supplement), 6 articles (86%) had low risk of bias and 1 had moderate risk of bias (Newcastle-Ottawa Scale values, 5-8).
Table 1. Characteristics of Included Studies

<table>
<thead>
<tr>
<th>Source</th>
<th>Study Design (Country)</th>
<th>Setting; Coverage</th>
<th>Study Years (Follow-up, y)</th>
<th>No. of Participants with AN</th>
<th>Characteristics of Participants by Sex; Age; Race/Ethnicity; Parity Status</th>
<th>No. of Cancer Cases</th>
<th>Main Cancer Outcome</th>
<th>Site-Specific Cancer Exposure</th>
<th>Outcome Definitions Comparator</th>
<th>End Point Measure</th>
<th>Adjustment for Confounding Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mellemkjaer et al, 2001</td>
<td>Retrospective cohort (Denmark)</td>
<td>Inpatient; population-based</td>
<td>1970-1996 (11.7)</td>
<td>2337</td>
<td>92.0% girls and women; most aged 10-24 y; NA; NA</td>
<td>27</td>
<td>All incidence</td>
<td>Yes</td>
<td>ICD-8 code 306.5; ICD-7 codes 104-205</td>
<td>General population</td>
<td>SIR</td>
</tr>
<tr>
<td>Korndörfer et al, 2003</td>
<td>Retrospective cohort (United States)</td>
<td>Community; population-based</td>
<td>1935-2000 (27.1)</td>
<td>208</td>
<td>92.8% women; mean age, 21.5 y; 100% white; NA</td>
<td>3 Cancer-related deaths</td>
<td>All mortality</td>
<td>No</td>
<td>DSM-III-R codes unreported</td>
<td>ICD-9 codes</td>
<td>General population</td>
</tr>
<tr>
<td>Michels and Ekbom, 2004</td>
<td>Retrospective cohort (Sweden)</td>
<td>Inpatient; population-based</td>
<td>1965-2000 (13.3)</td>
<td>7303</td>
<td>100% girls and women; most aged &lt;20 y; NA; 73% nulliparous</td>
<td>52</td>
<td>All incidence</td>
<td>Yes</td>
<td>ICD-7 codes 316.99 and 784.09; ICD-8 code 306.5; ICD-9 code 307B</td>
<td>General population</td>
<td>SIR</td>
</tr>
<tr>
<td>Karaminis et al, 2014</td>
<td>Retrospective cohort (Sweden)</td>
<td>Inpatient; population-based</td>
<td>1973-2003 (15.2)</td>
<td>6009</td>
<td>100% women; mean age, 26.4 y; NA; 65% nulliparous</td>
<td>74</td>
<td>All incidence and all mortality</td>
<td>Yes</td>
<td>ICD-8 code 306.5; ICD-9 code 307B; ICD-10 codes F50.0 and F50.1</td>
<td>General population</td>
<td>SIR</td>
</tr>
<tr>
<td>Brewster et al, 2015</td>
<td>Retrospective cohort (United Kingdom)</td>
<td>Inpatient; population-based</td>
<td>1981-2012 (13.9)</td>
<td>2138</td>
<td>60.5% women; mean age, 23.8 y; NA; NA</td>
<td>15</td>
<td>Specific incidence</td>
<td>Yes</td>
<td>ICD-9 codes 307.1 and 307.5; ICD-10 code F50</td>
<td>General population</td>
<td>SIR</td>
</tr>
<tr>
<td>Mellemkjaer et al, 2015</td>
<td>Retrospective cohort (Denmark, Finland and Sweden)</td>
<td>Inpatient; population-based</td>
<td>1968-2011 (12.6)</td>
<td>24332</td>
<td>93.1% women; 63% &lt;20 y; NA; 64% nulliparous</td>
<td>389</td>
<td>All incidence</td>
<td>Yes</td>
<td>ICD-8 code 306.5; ICD-9 code 307; ICD-10 codes F50.0 and F50.1</td>
<td>General population</td>
<td>IRR and HR</td>
</tr>
<tr>
<td>O’Brien et al, 2017</td>
<td>Prospective cohort (United States)</td>
<td>Community; multicenter</td>
<td>2003-2009 (5.4)</td>
<td>275</td>
<td>100% women; mean age, 51.7 y; 90% white, 4% African American, 4% Hispanic, 4% other; NA</td>
<td>2</td>
<td>Specific incidence</td>
<td>Yes</td>
<td>Interview with patient report, DSM-5</td>
<td>Validated diagnoses using medical records</td>
<td>Participants without history of eating disorder</td>
</tr>
</tbody>
</table>

Abbreviations: AN, anorexia nervosa; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised); DSM-5, Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition); HR, hazard ratio; ICD, International Classification of Diseases; IRR, incidence rate ratio; NA, not available; SIR, standardized incidence ratio; SMR, standardized mortality ratio.
Meta-analyses
We found no difference in all cancer incidence between patients with anorexia nervosa and the general population (4 studies in women; RR, 0.97; 95% CI, 0.89-1.06; \( P = .53; I^2, 0\%; 95\% \text{ PI}, 0.80-1.18\); moderate confidence) (Table 2 and Figure 3). Only 2 studies included data on cancer risk for male participants (RR, 1.09; 95% CI, 0.73-1.65; \( P = .67; I^2, 0\%; \text{ low confidence})
and 2 included data on cancer risk among both sexes combined (RR, 0.97; 95% CI, 0.88-1.07; \( P = .54; I^2, 0\%; \text{ low confidence})
Meta-analysis for all cancer mortality was not possible, with only 1 study in women (RR, 2.00; 95% CI, 1.30-2.90; \( P = .001; I^2, 0\%\); low confidence) and 1 study in both sexes combined (RR, 0.39; 95% CI, 0.08-1.13; \( P = .16; I^2, 0\%\); low confidence).

In terms of the 22 site-specific cancers, a minority of associations of anorexia nervosa with risk of developing cancer or death of cancer have supporting evidence (Table 2; eTable 8 in the Supplement). Anorexia nervosa was associated with decreased breast cancer incidence compared with the general female population (5 studies in women; RR, 0.60; 95% CI, 0.50-0.80; \( P < .001; I^2, 0\%; 95\% \text{ PI}, 0.44-0.83\); high confidence). Conversely, we found anorexia nervosa was potentially associated with an increased risk of developing lung cancer (3 studies in women; RR, 1.50; 95% CI, 1.06-2.12; \( P = .001; I^2, 0\%\); 95% PI, 0.19-16.46; low confidence) and esophageal cancer (2 studies in women; RR, 6.10; 95% CI, 2.30-16.18; \( P < .001; I^2, 0\%; \text{ low confidence})

No differences were found for any of the other specific sites of cancer investigated through meta-analyses, including cancer of the brain and central nervous system, cervical cancer, lip and oral

![Figure 2. Treemap Summarizing the Amount of Data According to Site-Specific Cancers](image-url)
cavity cancer, lymphoid and hematopoietic cancer, malignant skin melanoma, other skin cancer, pancreatic cancer, stomach cancer, and cancer of the thyroid gland (Table 2). Meta-analysis for 10 site-specific cancers was not possible; only 1 study included outcome data on bladder cancer, bone and articular cartilage cancer, colorectal cancer, gallbladder cancer, kidney cancer, liver cancer, ovarian cancer, prostate cancer, testicular cancer, and uterus cancer (eTable 5 in the Supplement).

Additional Analyses
The full details of the additional analyses are reported in eFigures 1-9 in the Supplement. We noted that the results were potentially different when we examined the outcomes by considering cancer types according to association with smoking or sex hormones. An increased risk of smoking-related

<table>
<thead>
<tr>
<th>Outcome of Interest</th>
<th>Studies, No.</th>
<th>Participants With Anorexia Nervosa, No.</th>
<th>Cancer Cases, No.</th>
<th>Pooled RR (95% CI)</th>
<th>RR of Largest Study Estimate (95% CI)</th>
<th>P Value for Effect Estimate</th>
<th>95% Prediction Interval</th>
<th>P Value for Heterogeneity Confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incidence in both sexes</td>
<td>2</td>
<td>26 669</td>
<td>416</td>
<td>0.97 (0.88-1.07)</td>
<td>0.98 (0.88-1.08)</td>
<td>.54</td>
<td>0 (NA)</td>
<td>NA .40 Low (risk unlikely)</td>
</tr>
<tr>
<td>Incidence in women</td>
<td>4</td>
<td>38 117</td>
<td>517</td>
<td>0.97 (0.89-1.06)</td>
<td>0.97 (0.88-1.08)</td>
<td>.53</td>
<td>0 (0-85)</td>
<td>0.80-1.18 .57 Moderate (risk unlikely)</td>
</tr>
<tr>
<td>Incidence in men</td>
<td>2</td>
<td>1864</td>
<td>25</td>
<td>1.09 (0.73-1.65)</td>
<td>1.08 (0.71-1.66)</td>
<td>.67</td>
<td>0 (NA)</td>
<td>NA .82 Low (not conclusive)</td>
</tr>
<tr>
<td>Site-Specific Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain and central nervous system</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incidence in both sexes</td>
<td>2</td>
<td>26 669</td>
<td>45</td>
<td>2.31 (0.58-9.12)</td>
<td>1.34 (0.95-1.89)</td>
<td>.23</td>
<td>72 (NA)</td>
<td>NA .06 Low (not conclusive)</td>
</tr>
<tr>
<td>Incidence in women</td>
<td>3</td>
<td>30 814</td>
<td>43</td>
<td>1.14 (0.81-1.62)</td>
<td>1.20 (0.80-1.70)</td>
<td>.45</td>
<td>0 (0-90)</td>
<td>0.12-10.89 .78 Low (not conclusive)</td>
</tr>
<tr>
<td>Incidence in men</td>
<td>2</td>
<td>1864</td>
<td>9</td>
<td>4.52 (0.89-22.97)</td>
<td>2.30 (1.00-5.20)</td>
<td>.07</td>
<td>68 (NA)</td>
<td>NA .08 Low (not conclusive)</td>
</tr>
<tr>
<td>Breast</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incidence in women</td>
<td>5</td>
<td>38 392</td>
<td>108</td>
<td>0.60 (0.50-0.74)</td>
<td>0.60 (0.50-0.80)</td>
<td>&lt;.001</td>
<td>0 (0-79)</td>
<td>0.44-0.83 .66 High (convincing)</td>
</tr>
<tr>
<td>Mortality in women</td>
<td>2</td>
<td>28 663</td>
<td>18</td>
<td>1.22 (0.31-4.77)</td>
<td>2.10 (1.30-3.60)</td>
<td>.78</td>
<td>69 (NA)</td>
<td>NA .07 Low (not conclusive)</td>
</tr>
<tr>
<td>Cervix, incidence in women</td>
<td>2</td>
<td>24 805</td>
<td>23</td>
<td>0.69 (0.45-1.07)</td>
<td>0.70 (0.40-1.00)</td>
<td>.10</td>
<td>0 (NA)</td>
<td>NA .85 Low (not conclusive)</td>
</tr>
<tr>
<td>Esophagus, incidence in women</td>
<td>2</td>
<td>24 805</td>
<td>6</td>
<td>6.10 (2.30-16.18)</td>
<td>5.10 (1.80-14.60)</td>
<td>&lt;.001</td>
<td>0 (NA)</td>
<td>NA .35 Low (not conclusive)</td>
</tr>
<tr>
<td>Lip and oral cavity, incidence in women</td>
<td>2</td>
<td>8160</td>
<td>2</td>
<td>2.00 (0.27-14.73)</td>
<td>3.20 (0.10-17.40)</td>
<td>.49</td>
<td>0 (NA)</td>
<td>NA .57 Low (not conclusive)</td>
</tr>
<tr>
<td>Lung</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incidence in both sexes</td>
<td>2</td>
<td>26 650</td>
<td>37</td>
<td>1.50 (1.06-2.12)</td>
<td>1.57 (1.07-2.30)</td>
<td>.02</td>
<td>0 (NA)</td>
<td>NA .58 Low (suggestive)</td>
</tr>
<tr>
<td>Incidence in women</td>
<td>3</td>
<td>30 814</td>
<td>38</td>
<td>1.77 (1.25-2.50)</td>
<td>1.60 (1.10-2.40)</td>
<td>.001</td>
<td>0 (0-90)</td>
<td>0.19-16.46 .54 Low (suggestive)</td>
</tr>
<tr>
<td>Lymphoid and hematopoietic, incidence in women</td>
<td>3</td>
<td>30 814</td>
<td>36</td>
<td>1.83 (0.78-4.30)</td>
<td>1.10 (0.80-1.60)</td>
<td>.16</td>
<td>57 (0-88)</td>
<td>0-17025 .10 Low (not conclusive)</td>
</tr>
<tr>
<td>Malignant skin melanoma, incidence in women</td>
<td>3</td>
<td>30 814</td>
<td>56</td>
<td>1.10 (0.84-1.44)</td>
<td>1.10 (0.80-1.50)</td>
<td>.49</td>
<td>0 (0-90)</td>
<td>0.19-6.39 .38 Low (not conclusive)</td>
</tr>
<tr>
<td>Other skin cancer, incidence in women</td>
<td>2</td>
<td>28 663</td>
<td>50</td>
<td>1.12 (0.82-1.52)</td>
<td>1.10 (0.80-1.50)</td>
<td>.48</td>
<td>0 (NA)</td>
<td>NA .56 Low (not conclusive)</td>
</tr>
<tr>
<td>Pancreas, incidence in women</td>
<td>2</td>
<td>24 805</td>
<td>7</td>
<td>1.94 (0.87-4.34)</td>
<td>1.80 (0.80-4.30)</td>
<td>.10</td>
<td>0 (NA)</td>
<td>NA .54 Low (not conclusive)</td>
</tr>
<tr>
<td>Stomach, incidence in women</td>
<td>2</td>
<td>8160</td>
<td>9</td>
<td>1.51 (0.73-3.11)</td>
<td>1.40 (0.60-2.70)</td>
<td>.27</td>
<td>0 (NA)</td>
<td>NA .48 Low (not conclusive)</td>
</tr>
<tr>
<td>Thyroid gland, incidence in women</td>
<td>3</td>
<td>30 814</td>
<td>18</td>
<td>0.97 (0.59-1.60)</td>
<td>0.90 (0.50-1.70)</td>
<td>.91</td>
<td>0 (0-90)</td>
<td>0.04-24.85 .88 Low (not conclusive)</td>
</tr>
</tbody>
</table>

Abbreviations: NA, not available; RR, risk rate.

* Cancer outcomes with 2 or more studies for meta-analysis.

b Prediction intervals and P 95% CIs were inestimable with fewer than 3 studies.
cancer incidence was observed in women with anorexia nervosa (4 studies; RR, 1.59; 95% CI, 1.17-2.16; \( P = .003; I^2, 58\% \)) but not with non–smoking-related cancers (4 studies; RR, 0.89; 95% CI, 0.73-1.09; \( P = .27; I^2, 40\% \)). In addition, anorexia nervosa was associated with decreased risk of developing cancers occurring in hormone-sensitive tissues compared with those without anorexia nervosa or the general population (5 studies; RR, 0.69; 95% CI, 0.55-0.87; \( P = .002; I^2, 27\% \)).

For the secondary outcome of breast cancer incidence, findings remained largely consistent after considering parity status (3 studies in parous women; RR, 0.48; 95% CI, 0.36-0.62; \( P < .001; I^2, 0\% \)) and age at receiving first diagnosis of anorexia nervosa (3 studies in women aged <20 years; RR, 0.30; 95% CI, 0.08-1.13; \( P = .08; I^2, 76\% \)) and age at receiving first diagnosis of anorexia nervosa (3 studies in women aged ≥20 years; RR, 0.63; 95% CI, 0.47-0.84; \( P = .002; I^2, 0\% \)), but some analyses may have led to insufficient statistical power.

No differences in conclusions were observed in post hoc sensitivity analyses after excluding studies that had potential overlapping populations. Finally, given the number of individual study estimates available per outcome (<10 studies) and reporting variability for specific sites of cancer events, assessment of small study effects (publication bias) for pooled analyses was considered not feasible.15

**Discussion**

To our knowledge, this is the first systematic review and meta-analysis to assess the totality of evidence regarding the association of anorexia nervosa with cancer risk. Although the scientific understanding of the extent of the epidemiological evidence underlying the associations of anorexia nervosa with cancer has developed within the past decades, only a minority of associations of...
anorexia nervosa with risk of developing cancer in specific cancer sites have supporting or suggestive evidence, to our knowledge. Fewer studies exist for the association of anorexia nervosa with risk of death from cancer, to our knowledge.

Our analysis does not support the possibility of a true inverse association of anorexia nervosa with cancer in general. Anorexia nervosa was associated with some cancers but not others. This may illustrate the fact that cancer is a complex, multifaceted, and heterogeneous disease with considerable variations in the scale of incidence (and mortality) of cancer types worldwide, particularly among young people. Breast cancer is the major contributor to the cancer burden among young adults globally. Findings from our meta-analysis suggest that anorexia nervosa was associated with decreased breast cancer incidence compared with the general female population, with high confidence. Conversely, we found that anorexia nervosa was potentially associated with increased risk of developing lung and esophageal cancer, but the evidence was judged as only low confidence.

The mechanisms of these patterns of risk have yet to be fully characterized. Most cancers are the result of many risk factors. Anorexia nervosa is a disorder associated with alterations in hormonal profiles. Reduced serum concentrations of estradiol and insulin-like growth factor 1 together with decreased lifetime exposure to estrogens owing to delayed puberty and hastened menopause might partially explain why young women with anorexia nervosa may have reduced risk of breast cancer and other hormone-sensitive tissue cancers. The extreme caloric restriction in anorexia nervosa could also affect the risk of some specific cancers but not cancer incidence in general. We noted inverse associations of breast cancer incidence with anorexia nervosa even after considering age at receiving first diagnosis of anorexia nervosa and parity status. Parity is widely recognized as protective against breast cancer, but breast cancer risk may be increased shortly after childbirth. A 2019 meta-analysis showed that compared with nulliparous women, parous women had an increased risk of breast cancer that peaked about 5 years after giving birth before decreasing after longer than 30 years. The overall pattern was driven by estrogen receptor-positive breast cancers.

Anorexia nervosa is a marker of calorie restriction characterized by an abnormally low body weight or low BMI. Various forms of reduced caloric intake, such as calorie restriction or fasting, have demonstrated a range of potential beneficial effects to help prevent malignancies and increase the efficacy of cancer therapies. Previous studies have shown associations of high BMI with many cancers. However, the decreased cancer risk we observed in our study was limited to estrogen-responsive tumors, and this may suggest that the caloric restriction seen in anorexia nervosa does not confer substantial cancer protection. The biological mechanisms underlying the association of BMI with the risk of breast cancer are complex, with opposing effects on premenopausal and postmenopausal risk of breast cancer. A 2016 International Agency for Research on Cancer report acknowledged consistent inverse associations of BMI with the risk of premenopausal breast cancer but inconsistent findings from studies that evaluated the effect of waist circumference or weight gain.

An increased risk was found for smoking-related cancers in women. However, the increased risk of developing lung or esophageal cancer does not seem to be attributable to a higher prevalence of smoking among women with anorexia nervosa. For example, in a 2016 meta-analysis evaluating the association of smoking prevalence with eating disorders, people with bulimia nervosa were significantly more likely to be lifetime smokers than healthy controls but not people with anorexia nervosa. Similarly, there was no difference in the proportion of current smokers among people with anorexia nervosa and healthy controls, while there was an increased proportion of current smokers among people with bulimia nervosa compared with healthy controls. These findings suggest that there may be a need for continued surveillance of symptoms suggestive of cancers of the respiratory tract system among patients with anorexia nervosa and for identification and evaluation of evidence-based health promotion interventions in patients with anorexia nervosa.
A number of noncausal explanations have been offered to account for the association of anorexia nervosa with cancer. Psychiatric comorbidity is common in anorexia nervosa and could affect cancer development or diagnosis. The presence of dense breast tissue may increase the risk of developing breast cancer. However, the role that the density of breast tissue may play in cancer development remains underexplored in anorexia nervosa and requires further research. Patients with anorexia nervosa might experience decreased rates of cancer screening as their condition worsens. Symptoms of anorexia nervosa might mask symptoms of cancer, and patients might be less willing to undergo examinations, such as mammograms. Some may suggest that since patients with anorexia nervosa have a higher mortality rate than the general population, those who survive anorexia nervosa may also be less susceptible to dying of cancer compared with the general population. However, we found no decreased all-cancer incidence rates in cohort studies, so this is an unlikely explanation.

**Limitations**

There are some limitations to be noted regarding our study. Similar to other meta-analyses of observational studies, there is methodological and clinical heterogeneity in the included studies in design, patient populations, and outcomes. We used study-level data instead of individual patient data, so the small number of studies and events for most site-specific cancers limited the sensitivity analyses that could be conducted to account for heterogeneity in the absence of patient-level data. Furthermore, our results might have limited generalizability because the cohort studies were mostly conducted in Western and Northern countries, and there were no reports from low- to middle-income countries with lower prevalence and incidence of anorexia nervosa. Meta-analysis of observational studies are prone to bias and confounding factors, including family history of cancer, smoking, alcohol, physical activity, and nutritional deficiency, that are inherent in the individual studies. Although we adopted reproducible definitions that will enhance cross-study comparisons, our study was challenged by the reporting of events in studies. None of the individual studies examined and reported all of the cancer outcomes of interest. Also, incomplete reporting was common in the literature and limited our possibilities to optimally synthesize the data for some specific cancers. It is important that future observational studies thoroughly report the methods and results for all outcomes of interest to ensure inclusion in future evidence syntheses. Reporting guidelines, such as the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline, should be rigorously adopted and implemented for individual study reports. Small study effects (ie, publication bias) were not quantitatively assessed, as there were inadequate numbers of included studies to properly assess a funnel plot or use more sophisticated regression-based methods. Further insights may be gained from analyses of large clinical and administrative databases with the power to examine the association of anorexia nervosa with specific cancers.

**Conclusions**

The association of anorexia nervosa with the risk of cancer has been studied in the biomedical literature. In general, we had low confidence in observational associations of anorexia nervosa with the risk of 20 outcomes, but there was supporting evidence from meta-analysis for 2 outcomes (all cancer combined and breast cancer). Other associations could also be valid (eg, lung cancer and esophageal cancer), but there is still uncertainty about the associations and the role of modifiable risk factors. There is still paucity of epidemiological data in many of the explored associations, and the number of individual studies is limited for most cancer outcomes. To draw firmer conclusions, we need more prospective cohort studies and large collaborations with better assessment of the complex connections among anorexia nervosa, losing body weight, and cancer.
Funding/Support
This study was supported by the Generalitat Valenciana and Carlos III Health Institute. Drs Catalá-López and Tabarés-Seisdedos received funding from the Generalitat Valenciana, the Spanish Ministry of Science, Innovation and Universities (CIBERSAM), and the Carlos III Health Institute. Dr Driver received support from a merit review grant from the US Department of Veterans Affairs. Dr Page received support from an early career fellowship from the Australian National Health and Medical Research Council. Dr Hutton received support from a new investigator award from the Canadian Institutes of Health Research and the Canadian Drug Safety and Health Research Institute, Centro de Investigación en Red de Salud Mental (CIBERSAM), Valencia, Spain (Catalá-López, Forés-Martos, Macías Saint-Gerons, Tabarés-Seisdedos); Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (Catalá-López, Hutton); Geriatric Research Education and Clinical Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts (Driver); Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (Driver); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (Driver); School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia (Page); School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada (Hutton); Instituto Aragonés de Ciencias de la Salud, Red de Investigación en Servicios de Salud en Enfermedades Crónicas, Zaragoza, Spain (Ridao); Department of History and Science, and Documentation, University of Valencia, Valencia, Spain (Alonso-Arroyo); Unidad de Investigación e Investigación Social y Sanitaria, University of Valencia, Spanish National Research Council, Valencia, Spain (Alonso-Arroyo); Directorate General for Public Health, Regional Health Council, Madrid, Spain (Génova-Maleras); Health Services and Policy Research Group, Exeter Collaboration for Academic Primary Care, University of Exeter Medical School, University of Exeter, Exeter, United Kingdom (Valderas); Hospital Clinic, Universitat de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Vieta); Life Sciences Department, Barcelona Supercomputing Center, Barcelona, Spain (Valencia).

Author Affiliations: Department of Health Planning and Economics, National School of Public Health, Institute of Health Carlos III, Monforte de Lemos 5, Madrid 28029, Spain (Catalá-López, Hutton); Department of Medicine, University of Valencia, INCLIVA Health Research Institute, Centro de Investigación en Red de Salud Mental (CIBERSAM), Valencia, Spain (Catalá-López, Forés-Martos, Macías Saint-Gerons, Tabarés-Seisdedos); Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (Catalá-López, Hutton); Geriatric Research Education and Clinical Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts (Driver); Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (Driver); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (Driver); School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia (Page); School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada (Hutton); Institut d’Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Vieta); Life Sciences Department, Barcelona Supercomputing Center, Barcelona, Spain (Valencia).

Author Contributions: Dr Catalá-López had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Catalá-López, Driver, Page, Tabarés-Seisdedos.


Drafting of the manuscript: Catalá-López.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Catalá-López.

Obtained funding: Tabarés-Seisdedos.


Supervision: Catalá-López, Driver, Tabarés-Seisdedos.

Conflict of Interest Disclosures: Dr Vieta reported receiving grants outside this work from AB Biotics, Abbott Laboratories, AstraZeneca, the Brain and Behaviour Research Foundation, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Ferrer, Forest Research Institute, Gedeon Richter, GlaxoSmithKline, Janssen Pharmaceutica, Lundbeck, Pfizer, Roche Holding, Sage Therapeutics, Sanofi, Servier Laboratoires, Shire, the Spanish Ministry of Science, Innovation and Universities (CIBERSAM), Horizon 2020, and the Stanley Medical Research Institute and reported receiving personal fees outside this work from Abbott Laboratories, Allergan, Angelini Pharma, AstraZeneca, Bristol-Myers Squibb, Farmindustria, Ferrer, Gedeon Richter, GlaxoSmithKline, Janssen Pharmaceutica, Lundbeck, Otsuka Pharmaceutical, Pfizer, Roche Holding, Sage Therapeutics, Sanofi, Servier Laboratoires, Shire, Sunovion, and Takeda Pharmaceutical Company. Dr Tabarés-Seisdedos reported receiving grants from Generalitat Valenciana and Carlos III Health Institute. No other disclosures were reported.

Funding/Support This study was supported by the Generalitat Valenciana and Carlos III Health Institute. Drs Catalá-López and Tabarés-Seisdedos received funding from the Generalitat Valenciana, the Spanish Ministry of Science, Innovation and Universities (CIBERSAM), and the Carlos III Health Institute. Dr Driver received support from a merit review grant from the US Department of Veterans Affairs. Dr Page received support from an early career fellowship from the Australian National Health and Medical Research Council. Dr Hutton received support from a new investigator award from the Canadian Institutes of Health Research and the Canadian Drug Safety and Health Research Institute.
Effectiveness Network. Dr Ridao received funding from the Spanish Health Services Research on Chronic Patients Network and the Carlos III Health Institute.

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**REFERENCES**


Association of Anorexia Nervosa With Risk of Cancer

22. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549. doi:10.1136/bmj.d549


SUPPLEMENT.

eTable 1. Definitions of Specific Cancer Site Outcomes
eTable 2. Methods Clarifications and Modifications From the Protocol
eTable 3. Search Strategy
eTable 4. List of Excluded Studies
eTable 5. Results of Individual Studies
eTable 6. Methodological Quality Assessment of Included Studies Using Newcastle-Ottawa Scale
eTable 7. Grading Certainty or Credibility of Evidence for Summary Estimates
eTable 8. Summary Statistics of Risk of Cancer for People With Anorexia Nervosa

eFigure 1. Meta-analysis of Breast Cancer Incidence and Mortality

eFigure 2. Meta-analysis of Breast Cancer Incidence and Subgroup Analysis by Parity Status and Age at First Diagnosis of Anorexia Nervosa

eFigure 3. Meta-analysis of Lung Cancer Incidence

eFigure 4. Meta-analysis of Lymphoid and Hematopoietic Cancer Incidence and Mortality

eFigure 5. Meta-analysis of Malignant Skin Melanoma Incidence and Mortality

eFigure 6. Meta-analysis of Smoking-Related Cancers

eFigure 7. Meta-analysis of Non-Smoking-Related Cancers

eFigure 8. Meta-analysis of Cancers Occurring in Hormone-Sensitive Tissues

eFigure 9. Sensitivity Analysis